Wegovy® pill UK

The Wegovy pill is an oral prescription-only weight management medication taken once daily. The active ingredient of oral Wegovy is semaglutide, the same active ingredient found in the weekly Wegovy injection.

Oral Wegovy uses SNAC coating technology to protect semaglutide as it passes through your stomach. This allows the medication to be absorbed into your bloodstream. Without SNAC, stomach acid would break down the medication before it could work.

The pill uses a higher daily dose (25 mg) for maintenance because less medication is absorbed orally than through injection, achieving a similar effect as the 2.4 mg weekly injection.

Wegoy pill was approved in the UK by the MHRA on the 11 June 2026.

Wegovy mimics glucagon-like peptide-1 (GLP-1), a hormone your gut releases after eating.

The Wegovy pill works by:

• Reducing appetite: It signals to your brain that you're full, helping you feel satisfied with smaller portions and reducing cravings between meals

• Slowing digestion: Food stays in your stomach longer, prolonging feelings of fullness and reducing the urge to snack

• Supporting blood sugar control: It helps regulate post-meal blood sugar levels, which can reduce energy crashes and hunger spikes

Wegovy weight loss pills are an effective treatment when combined with healthy eating and increased physical activity.

Most people notice appetite changes within the first 1-4 weeks. Measurable weight loss typically becomes apparent from week 5-6 onwards as your dose increases.

The Wegovy pill follows a 12-week dose escalation schedule, starting at 1.5 mg daily and increasing every 30 days until you reach the 25 mg maintenance dose. This gradual approach helps your body adjust and reduces side effects.

In clinical trials, participants taking the 25 mg dose achieved an average weight loss of 13.6% over 64 weeks.

Individual results vary and depend on consistent daily use, following administration instructions, and maintaining healthy lifestyle changes alongside treatment.

Wegovy pills are suitable for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as high blood pressure, obstructive sleep apnoea (OSA) or high cholesterol.

If you're of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean background, you may be eligible at a BMI of 27 or above (instead of 30).

Wegovy pills work best alongside a healthy balanced diet and increased physical activity. Our clinical team will support you throughout your weight management journey.

Wegovy pills are not suitable for everyone. Every assessment is thoroughly reviewed to ensure our patients’ safety.  

If you have any concerns, health conditions or queries regarding the use of Wegovy, our clinician team are here to advise you every step of the way.  

You should not take Wegovy if you: 

• Are pregnant, planning to become pregnant, or breastfeeding 

• Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) 

• Are allergic to any of the ingredients of the medication  

You should discuss treatment carefully with your prescriber if you have: 

• Severe stomach problems or a history of gastroparesis 

• Type 1 diabetes or a history of diabetic ketoacidosis 

• Severe kidney disease 

• Severe liver disease 

• A history of pancreatitis 

• Diabetic retinopathy or other vision problems

• Gallbladder problems

Your prescriber will review your full medical history during your consultation to ensure Wegovy pills are safe and effective for you.  

Always inform your prescriber of any existing health conditions or medications you're taking.

In the OASIS 4 clinical trial, adults taking the 25 mg Wegovy pill achieved an average of 13.6% over the 64 weeks. Participants who stayed on treatment throughout the study achieved an average of ~17% weight loss.

Breaking down the results:

• 63% of participants lost 10% or more of their body weight

• 30% of participants lost 20% or more of their body weight

• Weight loss was accompanied by improvements in blood pressure, blood sugar control, and cholesterol levels

The results of oral Wegovy are comparable to those seen with the weekly Wegovy injection. Weight loss develops gradually over the course of treatment, with most people noticing meaningful visible changes from around 3 months onwards once the maintenance dose is reached.

Individual results depend on several factors including your starting weight, how well you tolerate the medication, and how consistently you maintain healthier eating patterns, increased physical activity and follow administration instructions.

Our clinical team will monitor your progress and adjust your treatment plan as needed to help you achieve your weight loss goals.

Wegovy pills follow a gradual dose escalation schedule over 12 weeks to help your body adjust and minimise side effects:

Your prescriber will start you on the lowest dose and increase it every 30 days as tolerated.

If you experience persistent side effects on Wegovy pills at any stage, your prescriber may adjust the schedule or recommend stepping down to a lower dose or switching to the weekly Wegovy injection at a lower equivalent dose.

The 25 mg maintenance dose is designed for long-term use. Weight regain often happens when treatment stops before healthy habits are fully established, which is why ongoing support from our clinical team helps you maintain your progress.

Missing a dose occasionally happens, and it's important to know how to get back on track safely.

If you miss a dose:

• Skip the missed dose entirely - do not take it later in the day

• Resume your normal schedule the next morning

• Do not take two tablets the following day to make up for the missed dose

If you vomit after taking your tablet, do not take another dose. Resume your normal schedule the next morning.

If you miss multiple doses or are unsure what to do, contact our clinical team for guidance.

Taking the Wegovy pill correctly ensures the medication is absorbed properly.

Follow these steps every day:

• Take it first thing in the morning on an empty stomach, as soon as you wake up.

• Use no more than 120 ml (4 oz) of plain water - not sparkling, flavoured, or hot water.

• Swallow the tablet whole - do not crush, chew, or split the tablet.

• Wait at least 30 minutes before eating, drinking anything, or taking any other medications or supplements.

• Take it at the same time each day for consistent results.

• Keep tablets in their blister packs until you are ready to take them. Do not transfer them to a pill organiser box, as this can expose them to moisture.

The 30-minute fasting window is critical. Food, coffee, juice, or other medications taken too soon can interfere with absorption and reduce how well the medication works, or stop it working altogether.

If you take other medications in the morning, set an alarm to remind yourself when the fasting period ends.

Both formats contain the same active ingredient semaglutide and produce similar results. The difference is routine, not effectiveness.

 The 1.3% gap between pill and injection is unlikely to be clinically meaningful for most people. The higher dose injection (7.2 mg) is an option for those who do not reach their goals on the standard dose.

The main practical difference is the daily fasting requirement with the pill. The injection has no food restrictions and is taken once weekly. For a full breakdown, read our Wegovy pill vs Wegovy injection comparison guide.

Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors, which is why it produces greater body weight loss than Wegovy in trials.

 For a full breakdown, read our Wegovy pill vs Mounjaro comparison guide.

Saxenda (liraglutide) is a daily injection made by the same manufacturer as Wegovy, Novo Nordisk. Both are GLP-1 receptor agonists, but Wegovy grips the GLP-1 receptor more strongly and stays active for longer.

 For a full breakdown, read our Wegovy pill vs Saxenda comparison guide.

Foundayo is a once-daily oral GLP-1 pill made by Eli Lilly, FDA-approved in April 2026. Like the Wegovy pill, it targets GLP-1 receptors to reduce appetite and slow digestion - but it is a small molecule drug that does not require SNAC coating, meaning it can be taken with food at any time of day.

Key differences:

• Weight loss: the Wegovy pill produced 13.6% average weight loss over 64 weeks in OASIS 4. Foundayo produced 11.2% over 72 weeks in ATTAIN-1. An indirect comparison (ORION) found roughly 3 percentage points more weight loss with the Wegovy pill

• Convenience: Foundayo has no fasting rules. The Wegovy pill requires a 30-minute fast every morning

• Safety record: Oral semaglutide with SNAC technology has been used in the diabetes tablet Rybelsus since 2020, giving it over five years of real-world data. Foundayo is newer with less long-term evidence

For a full breakdown, read our Wegovy pill vs Foundayo comparison guide

Digestive side effects are the most common with Wegovy pills, affecting nearly three in four participants in the OASIS 4 trial. Based on trial data, reported rates on the 25 mg dose compared to placebo were:

Nausea is typically the first to appear, usually within the first few days of starting or increasing your dose and is often the first to ease. Eating smaller meals, avoiding fatty or spicy food, and not lying down after eating can all help.

For a full breakdown of what to expect and how to manage digestive symptoms, see our Wegovy pill side effects guide.

Constipation affects around 1 in 5 people and can persist longer than nausea. Increasing fibre intake and staying well hydrated helps. If it persists, contact our clinical team.

Alongside digestive symptoms, other common side effects of Wegovy pills include:

• Headache

• Fatigue

• Dizziness

• Hair loss

These are most likely during dose escalation and tend to improve over time.

Headaches, dizziness, and fatigue are often linked to eating less or mild dehydration rather than a direct effect of the medication.

Hair loss, where it occurs, is more likely a response to rapid weight loss than to the medication itself and typically regrows once weight stabilises.

Staying well hydrated is important for everyone taking GLP-1 treatments. GLP-1 treatments reduce appetite, which can mean you drink less without realising it - and when combined with vomiting or diarrhoea, dehydration becomes a real clinical risk.

Aim for at least 1.5 to 2 litres of water daily. Good hydration also supports your weight management by helping regulate appetite and energy levels.

Signs of dehydration to watch for:

• Dark urine 

• Dry mouth 

• Dizziness 

• Feeling lightheaded 

Increase your fluid intake during dose escalation if you are experiencing digestive symptoms. If you cannot keep fluids down, call NHS 111 rather than waiting for symptoms to pass.

Serious side effects from Wegovy pills are uncommon, but some require immediate action. Do not wait to see if these symptoms pass on their own.

• Pancreatitis: severe stomach pain that spreads to your back, with or without vomiting, may be a sign of pancreatitis. In January 2026, the MHRA strengthened its warnings on pancreatitis risk for all GLP-1 medicines after rare reports of severe and fatal cases. It may also present as high temperature.

  • If you experience these symptoms, stop Wegovy pills immediately and go to A&E.

• Sudden vision changes (NAION): in February 2026, the MHRA issued a safety warning linking semaglutide to NAION, a rare eye condition that can cause sudden painless vision loss in one eye.

  • Go to your nearest eye casualty unit or A&E urgently if you notice any sudden change in your vision.

• Gallbladder problems: Around 2.5% of people on the Wegovy pill developed gallstones in OASIS 4, compared to 1% on placebo. Watch for upper right abdominal pain, nausea, and fever.

  • Contact your GP or our clinical team if you experience these symptoms.

• Thyroid changes: Wegovy pills are not suitable for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). 

  • Tell your prescriber before starting treatment if this applies to you.

• Kidney injury: While Wegovy pills do not directly damage the kidneys, severe dehydration caused by vomiting or diarrhoea can. This is why staying hydrated throughout treatment is a clinical priority, not just comfort advice.

Semaglutide has an established safety record at lower doses used for type 2 diabetes. The SELECT trial, which followed over 17,600 adults for more than three years, found Wegovy reduced the risk of serious heart health events by 20% in people with obesity and established heart disease.

The 25 mg weight management dose is newer, and long-term data at this dose is still emerging. Our clinical team monitors your progress throughout treatment and will flag any concerns.

Call 999 or go to A&E if you experience:

• Severe stomach pain spreading to your back. May present a high temperature - possible pancreatitis

• Swelling of the face, lips, tongue or throat, or difficulty breathing - possible allergic reaction

• Sudden vision loss or rapid blurring in one eye - possible NAION

• New or worsening thoughts of self-harm or suicide - or call the Samaritans on 116 123 at any time

Call NHS 111 if you:

• Cannot stop vomiting or cannot keep fluids down

• Are unsure whether a side effect needs urgent attention

• Experience dizziness, shakiness, or confusion, particularly if you take diabetes medication

See your GP the same day if you:

• Notice yellowing of your skin or the whites of your eyes

• Have persistent or worsening low mood or anxiety

If you are unsure at any point, our clinical team is here to help before you consider stopping Wegovy pills.

Do not take Wegovy pills if you:

• Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

• Are pregnant, planning to become pregnant, or breastfeeding – all GLP-1 medication should be stopped at least 2 months before attempting to conceive

• Are allergic to semaglutide, SNAC coating, or any other ingredient in the tablet

• Have severe gastroparesis or significant gastrointestinal disease

• Have a history of vision problems related to your diabetes

• Have pancreatitis

Tell your prescriber about any medication you are taking including vitamins , supplements and over the counter medications, particularly if you take any of the following: 

• Levothyroxine: thyroid hormone levels should be monitored

• Warfarin or other anticoagulants: oral Wegovy may affect INR through dietary changes and changes in gastric motility

• Anti-epilepsy medicines: some epilepsy medicines such as phenytoin require careful monitoring as they have a narrow dosing range

• Ciclosporin: narrow therapeutic index; dose timing may need adjustment

• Other morning medications: any oral medication requiring rapid absorption should be taken at least 30 minutes after the Wegovy pill, once the fasting window has passed

The primary interaction concern with oral Wegovy is the slowing of gastric emptying, which can affect how quickly other medications are absorbed. For a full list of interactions, the emc Wegovy SmPC and NHS Specialist Pharmacy Service are the recommended clinical references.

Wegovy does not reduce the effectiveness of combined oral contraceptives. A dedicated absorption study confirmed that the medication does not meaningfully affect the absorption of the hormones in the contraceptive pill.

However, because the Wegovy pill requires a 30-minute fasting window after taking it, your contraceptive pill should be taken at least 30 minutes after your Wegovy pill to avoid any effect on absorption timing.

If you experience recurrent vomiting during treatment, speak to our clinical team about whether additional contraceptive precautions are advisable during that period.

 Keep Wegovy pills out of reach of children. Do not use after the expiry date printed on the packaging.

Travelling with Wegovy pills:

• Wegovy pills can be carried in hand luggage - no cold-chain packaging required

• Keep tablets in their original packaging and blister packs when travelling

• Avoid leaving tablets in a hot car or in direct sunlight for extended periods

We deliver Wegovy pills directly to your door in secure, discreet packaging. Keep Wegovy pills in their blister packs until you are ready to use them to protect the tablets from moisture.

Switching between the Wegovy pill and injection is straightforward as both contain semaglutide. Novo Nordisk have confirmed that the 25 mg pill is equivalent to the 2.4 mg weekly injection, giving a clear dose equivalence starting point.

If you are on the 1.7 mg injection or above, you can switch directly to the 25 mg maintenance pill. For patients on lower doses, the equivalent Wegovy pill dose is:

Switching from the 2.4 mg or 7.2 mg injection to the 25 mg pill:

• Take your final injection as normal

• Wait seven days (the day you would normally take your next injection)

• Start the 25 mg Wegovy pill the following week, After the 7 day wait start the daily 25mg Wegovy pill. If you take your last injection on a Monday you can start the Wegovy pill the following Monday

• Taken first thing in the morning on an empty stomach with no more than 120 ml of plain water

• Wait 30 minutes before eating, drinking, or taking other medications

The daily fasting routine is what most people find harder than the medication change itself.

Speak to our clinical team if you are unsure which format suits you best.

When switching from the pill back to an injectable - whether Wegovy or Mounjaro - a more cautious approach is needed. Because the pill has lower and more variable bioavailability (absorption into the bloodstream) than a subcutaneous injection, the transition to a more stable delivery route carries a higher risk of side effects if dose equivalence is applied directly. If you experienced side effects on the pill, your prescriber will start you at a lower injection dose.

Wegovy pill to Wegovy injection

*Dependent on side effects experienced on the Wegovy pill. Your prescriber will review assesment and confirm your starting dose.

Wegovy pill to Mounjaro

Mounjaro targets both GLP-1 and GIP receptors. Patients switching from the Wegovy pill will be GIP-naive, meaning the GIP action of Mounjaro is new to your system. For this reason, the switch is more conservative than the equivalent injection-to-pill journey.

Your prescriber will review your full treatment history before confirming your starting Mounjaro dose.

Mounjaro and Wegovy work differently - Mounjaro targets both GLP-1 and GIP receptors, Wegovy targets GLP-1 only - so there is no direct dose conversion from Mounjaro's mechanism. Equivalent doses have been extrapolated from Wegovy injection equivalence data.

Most patients on higher doses of Mounjaro - 7.5 mg or higher - may switch directly to the 25 mg maintenance pill.

Key things to know before switching:

• Washout period: allow one full week (7 days) between your last Mounjaro injection and your first Wegovy pill to avoid overlapping side effects

• Weight loss: expect slightly less than Mounjaro on average. The SURMOUNT-5 trial found Mounjaro 15 mg produced ~22.5% average body weight loss. The Wegovy pill 25 mg produced and average body weight loss os ~17% in the OASIS 4 trial, in line with the injection

• Hunger during the gap: appetite typically increases between stopping Mounjaro and reaching the Wegovy maintenance dose, but usually settles within a couple of months

The Wegovy pill price depends on the dose you are prescribed.

Starting dose is 1.5 mg and increases over the first 12 weeks before reaching the 25mg maintenance dose.

We are currently offering new patients £30 off - start consultation to pre-order now.

Prices for all treatments vary by dose and are reviewed regularly.

When you pre-order Wegovy pills you will need to complete our patient assessment form which normally takes around 5 minutes. At the end of the form, if you are eligible, you will be able to place your order and make your payment.

Our clinical team will check your assessment details, and once you have been approved your payment will be processed. At this point, your place in line for the Wegovy pills will be confirmed.

We are expecting Wegovy pills to be delivered to us by the manufacturer in a few weeks and delivery to start in July. As soon as we have more information about the delivery we will let you know.

Once we have received stock into our warehouse we will start dispatching to our patients on a first come, first served basis.

We are expecting a huge peak in demand for Wegovy pills so we recommend orders are placed as early as possible. We will keep patients informed every step of the way on their expected delivery date.

Yes. You do not need a GP referral to buy Wegovy pills. After completing a quick online clinical assessment a qualified prescriber will review your assessment and issue a prescription if suitable.

Yes. In the OASIS 4 trial, adults taking the 25 mg Wegovy pill lost an average of 13.6% of their body weight over 64 weeks, increasing to ~17% on continued treament, alongside a healthy diet and increased physical activity. 63% of participants lost 10% or more of their body weight.

Foundayo (orforglipron) is the closest alternative - a once-daily oral GLP-1 pill producing 11.2% average weight loss over 72 weeks in trials. Unlike the Wegovy pill, it can be taken with food.

Wegovy pill currently has the highest average weight loss in trials of any licensed oral weight loss pill in the UK  with 13.6% average weight loss over 64 weeks in clinical trials, rising to ~17% amoung those how continued treatment.